|
| Cabozantinib impurity 1DYH Basic information |
Product Name: | Cabozantinib impurity 1DYH | Synonyms: | N-[4-[(6,7-Dimethoxy-1-oxido-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide;Cabozantinib impurity 1DYH;1,1-Cyclopropanedicarboxamide, N-[4-[(6,7-dimethoxy-1-oxido-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-;4-(4-(1-((4-fluorophenyl)carbamoyl)cyclopropane-1-carboxamido)phenoxy)-6,7-dimethoxyquinoline 1-oxide ;N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)-6,7-dimethoxyquinolin-4-amine | CAS: | 1621681-63-7 | MF: | C28H24FN3O6 | MW: | 517.51 | EINECS: | | Product Categories: | | Mol File: | 1621681-63-7.mol | |
| Cabozantinib impurity 1DYH Chemical Properties |
density | 1.36±0.1 g/cm3(Predicted) | pka | 13.86±0.70(Predicted) |
| Cabozantinib impurity 1DYH Usage And Synthesis |
Uses | Cabozantinib N-oxide is a impurity of Cabozantinib (X745500), a medication used to treat medullary thyroid cancer. As well, it can be used in biological study. Computational network biological approach based on pathway cross-talk inhibition identified new synergistic drug combinations using raloxifene and cabozantinib for treatment of human breast cancer in xenograft mouse model. Potent c-MET inhibitor. |
| Cabozantinib impurity 1DYH Preparation Products And Raw materials |
|